Long-Term Survival After Fertility-Sparing Surgery for Epithelial Ovarian Cancer

Abstract

Fertility-sparing surgery is a reasonable alternative treatment for young women with stage I epithelial ovarian cancer desiring fertility preservation.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

“…[112][113][114] For a young patient who wishes to maintain fertility, a unilateral salpingooophorectomy (USO; preserving the uterus and contralateral ovary) may be adequate for select unilateral stage I tumors (stage 1A and 1C, but not stage 1B) and/or low-risk ovarian tumors (ie, early-stage, grade 1 tumors; borderline tumors; see LCOH-6, LCOH-9, LCOH-10; pages 1141, 1143, and 1144, respectively). [115][116][117][118][119][120] Comprehensive staging may not be necessary for select patients, such as those with borderline epithelial tumors (see LCOH-6, page 1141).…”

Fertility-Sparing Surgery for Young Women with Early-Stage Epithelial Ovarian Cancer

“…In most studies, including this review, fertility-sparing surgery has been defined as the preservation of ovarian tissue in one or both adnexa and the uterus in women of reproductive age [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39] (table 1). To date, 918 patients with EOC who underwent fertility-sparing surgery have been captured in the literature.…”

“…The safety of fertility-sparing surgery in women with stage IC and grade 3 EOC has not been determined, although the results of several recent series have suggested that fertility-sparing surgery is safe in patients with stage IC grade 1-2 EOC, regardless of the type of stage 1C (positive peritoneal cytology, capsule invasion or tumor rupture) [19,20,23,25,28,29,32,33,34,35,36,37,38,39]. Patients with preoperative or intraoperative tumor rupture, surface excrescences, or malignant cells in ascitic fluid or peritoneal washings are classified as having stage IC disease.…”

Aberrant Methylation of RASSF2A in Tumors and Plasma of Patients with Epithelial Ovarian Cancer

“…Because of the nonspecific symptoms and the lack of early diagnostic methods, EOC is extremely difficult to diagnose at an early stage. Nearly 70% of patients are diagnosed at an advanced stage (FIGOⅡ-Ⅳ), with a survival rate of 30-40% (Cannistra et al, 1993;Barnholtz-Sloan et al, 2003;Qiu H et al, 2011); however, if diagnosed at a localized stage (FIGOⅠ), the 5-year survical rate is 93% (Schlaerth et al, 2009). Therefore, a study on the molecular mechanism underlying ovarian cancer progression, including a search for a related target gene, is important for early diagnosis and effective therapy for ovarian cancer.…”